SodiUm Glucose co-trAnspoRt-2 inhibitioN diabeteS And and kidney function Loss in Type 1 diabetes: The "SUGARNSALT" Team Grant Program
Description: Diabetes is the most common cause of kidney failure in Canada, and requires either dialysis or a kidney transplant. Kidney failure leads to terrible suffering for patients, with a poor quality of life, equivalent to that seen with advanced colon cancer. In addition, kidney failure increases the likelihood of cardiovascular disease and premature death. Fortunately, new therapies called "SGLT2 inhibitors" have been discovered that reduce the risk of kidney failure and cardiovascular diseases in people with a kind of diabetes linked with being overweight, called "type 2 diabetes". These drugs may delay the need for dialysis by as much as 15 years, or prevent it entirely. Unfortunately, it is not known if these medicines are also beneficial for people with type 1 diabetes - also known as "juvenile diabetes". In this research program, we will perform a series of studies in people with type 1 diabetes. First, we will study kidney effects of SGLT2 inhibition in people with type 1 diabetes over a two year treatment period, including blood and urine tests that reflect kidney protection that doctors use in the clinic routinely. We will also perform research-based blood and urine tests to understand how these medications work over the long term, leading to a reduction in kidney damage. We will also examine ways to avoid side effects. As part of this study, we will check to see how patients feel about taking these medications, in terms of both benefits and side effects. Next, we will use Danish health records (where SGLT2 inhibitors can be used for type 1 diabetes) to determine if these therapies reduce the risk of kidney disease when used as part of routine care in type 1 diabetes. Finally, we will study the effectiveness of these medications as a long term kidney protective therapy using mathematical models. Overall, this program has the potential to reduce the risk of diabetes complications and improve the quality of life in people living with this serious condition.
Amount: CA$10,000
Funding type: research
Funder scheme: Team Grant: Diabetes Mechanisms and Translational Solutions - CIHR-KFOC - Diabetic Kidney Disease - LOI
Start date: 2021-05-01
End date: 2022-04-30
Investigator: David Cherney
Institution: Toronto General Hospital
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 176029_1
OpenAlex ID: G7970151019